NeuroOne Medical Technologies First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
NeuroOne Medical Technologies (NASDAQ:NMTC) First Quarter 2024 Results
Key Financial Results
Revenue: US$977.6k (down 38% from 1Q 2023).
Net loss: US$3.34m (loss widened by 93% from 1Q 2023).
US$0.14 loss per share (further deteriorated from US$0.11 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeuroOne Medical Technologies Earnings Insights
Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 13% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 6 warning signs for NeuroOne Medical Technologies (2 are concerning!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
